Key points are not available for this paper at this time.
Due to their great biocompatibility, biodegradability, and minimal immunogenicity, liposomes are now the most widely employed nanocarriers for a variety of hydrophobic and hydrophilic compounds that may be biologically active. Additionally, liposomes demonstrated improved drug solubility and regulated distribution. They also showed the ability to modify the surface of drugs for targeted, extended, and sustained release. Liposomes can be thought of as having developed from traditional, long-circulating, targeted, and immunological liposomes to stimuli-responsive and actively targeted liposomes based on their composition. More liposomes have advanced stages in clinical trials, and many liposomal-based drug delivery systems are currently clinically licensed to treat several disorders, including cancer, fungal infections, and viral infections. This review discusses the composition, preparation procedures, and clinical uses of liposomes.
Sakshi et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: